AI assistant
Ascelia Pharma Share Issue/Capital Change 2024
3132_rns_2024-09-30_7f1c0ce1-3b37-4cc4-a768-1135d70554f3.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
PRESS RELEASE
30 September 2024 15:25:00 CEST
Change in Number of Shares and Votes in Ascelia Pharma AB
During September, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the rights issue of units resolved by the Board of Directors on 10 July 2024 and approved by the Extraordinary General Meeting on 14 August 2024. As of 30 September 2024, the total number of shares in Ascelia Pharma amounts to 97,193,153 shares, whereof 96,079,722 are ordinary shares with one vote each and 1,113,431 are series C shares with 1/10 vote each. The total number of votes as of 30 September 2024 amounts to 96,191,065.1.
About us
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.
Contacts
Magnus Corfitzen, CEO Email: [email protected] Tel: +46 735 179 118
Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)
Email: [email protected] Tel: +46 735 179 116
This information was submitted for publication, through the agency of the contact persons set out above.
This information is information that Ascelia Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-09-30 15:25 CEST.